GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimeric Therapeutics Ltd (ASX:CHM) » Definitions » Inventories, Raw Materials & Components

Chimeric Therapeutics (ASX:CHM) Inventories, Raw Materials & Components : A$0.00 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Chimeric Therapeutics Inventories, Raw Materials & Components?

Chimeric Therapeutics's inventories, raw materials & components for the quarter that ended in Dec. 2023 was A$0.00 Mil.


Chimeric Therapeutics Inventories, Raw Materials & Components Historical Data

The historical data trend for Chimeric Therapeutics's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimeric Therapeutics Inventories, Raw Materials & Components Chart

Chimeric Therapeutics Annual Data
Trend Jun21 Jun22 Jun23
Inventories, Raw Materials & Components
- - -

Chimeric Therapeutics Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Inventories, Raw Materials & Components Get a 7-Day Free Trial - - - - -

Chimeric Therapeutics Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.


Chimeric Therapeutics (ASX:CHM) Business Description

Industry
Traded in Other Exchanges
Address
62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.

Chimeric Therapeutics (ASX:CHM) Headlines

No Headlines